Alnylam Pharmaceuticals (ALNY) Could Be 38% Undervalued After Mivelsiran Trial Progress
Alnylam Pharmaceuticals (ALNY) is in focus after presenting new mivelsiran data and trial updates at the Alzheimer’s Association International Conference, spotlighting its RNAi approach across multiple Alzheimer’s and cerebral amyloid angiopathy programs.
See our latest analysis for Alnylam Pharmaceuticals.
These Alzheimer’s and cerebral amyloid angiopathy updates land at a time when Alnylam Pharmaceuticals’ 1-year total shareholder return has declined 17.35%, while the 3-year and 5-year total shareholder returns of 36.37% and 51.88% indicate a stronger longer-term record.
If this kind of neuroscience progress has your attention, it could be a good moment to see what else is emerging in the sector by scanning 40 healthcare AI stocks
After a sharp year to date pullback, Alnylam Pharmaceuticals now trades at a steep discount to both analyst targets and some intrinsic value estimates. Is that discount a sign of excessive caution, or a fair reflection of the risks?
Most Popular Narrative: 38% Undervalued
On the widely followed narrative, Alnylam Pharmaceuticals’ fair value of $434.72 sits well above the last close at $271.77, setting up a valuation story that leans heavily on its RNAi pipeline and TTR franchise.
The rapid and robust uptake of AMVUTTRA for ATTR-CM in its first full quarter post-approval, combined with near-universal first-line payer access and minimal patient out-of-pocket costs, indicates a much larger addressable market for Alnylam's RNAi therapies as diagnostics and disease awareness improve, supporting sustained double-digit revenue growth.
Curious what sits behind that growth story for Alnylam Pharmaceuticals? The narrative leans on ambitious revenue expansion, rising margins and a rich future earnings multiple. The exact mix of those assumptions is what really drives that $434.72 fair value gap.
Result: Fair Value of $434.72 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on Alnylam Pharmaceuticals keeping Amvuttra pricing and margins resilient and avoiding pipeline setbacks that could challenge the current RNAi growth story.
Find out about the key risks to this Alnylam Pharmaceuticals narrative.
Another View on Alnylam Pharmaceuticals’ Valuation
The analyst narrative and fair value point to Alnylam Pharmaceuticals looking 38% undervalued, yet the current P/E of 67.4x tells a very different story. That multiple is roughly 4x the US Biotechs industry average of 16.9x and about double the estimated fair ratio of 34.5x, which suggests meaningful valuation risk if sentiment cools.
With Alnylam Pharmaceuticals also screening as expensive versus its peer average P/E of 31.6x, the question is whether the RNAi pipeline can keep investor expectations high enough to support this premium.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment around Alnylam Pharmaceuticals clearly split between opportunity and valuation risk, it makes sense to move quickly and test the numbers for yourself using the 4 key rewards.
Looking for more investment ideas beyond Alnylam Pharmaceuticals?
If Alnylam Pharmaceuticals has sharpened your focus, do not stop here. Broaden your watchlist now so you are not playing catch up on tomorrow's opportunities.
- Target potential mispricings early by scanning 49 high quality undervalued stocks before attention shifts and valuations adjust.
- Strengthen your downside protection by reviewing companies in the 79 resilient stocks with low risk scores that combine resilience with measured risk profiles.
- Get ahead of the crowd by searching the screener containing 19 high quality undiscovered gems where fewer eyes may mean more overlooked opportunities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com